Therapeutic strategies will be developed to engineer bifunctional compounds that either enhance BLOC1S1‐TDP‐43 binding to combat intracellular pathogens like Brucella or disrupt this interaction to restore nuclear TDP‐43 function in ALS/FTD models. Here, TARDBP is linked to frontotemporal dementia.